News Bell: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Starbucks Corporation (NASDAQ:SBUX)

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

The company announced its last quarter financial performance results on 11/07/2016. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) belongs to Medical sector that surged 0.72% in value when last trading session closed at $23.82. The company has a market capitalization of $4.63 Billion. The company’s stock has a Return on Assets (ROA) of -5.4 percent, a Return on Equity (ROE) of 37.1 percent and Return on Investment (ROI) of -62.9 percent. The company reached its 52-Week high of $23.85 on Jan 31, 2017 and 52-Week low of $4.37 on Feb 11, 2016.

Earnings per share (ttm) for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) according to Finviz Data is $-0.18.

This company was Downgrade by SunTrust on 11-Jan-17  to Hold.

The 8 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 24.00, with a high estimate of 24.00 and a low estimate of 14.00. The median estimate represents a +0.76% increase from the last price of 23.82.

Financial History:

Following Earnings result, share price were DOWN 15 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 58% percent of times. It has met expectations  0 times and missed earnings  5  times.

The consensus recommendation for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is 2.5. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.33. In comparison, the consensus recommendation 60 days ago was at 2.33, and 90 days ago was at 2 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Ariad Pharmaceuticals Inc. to have earnings per share of $-0.18.

Revenue is expected to range from 42.5 Million to 47.57 Million with an average of 44.15 Million.

Company Profile:

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology.  The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology.  The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

Starbucks Corporation (NASDAQ:SBUX):

Starbucks Corporation (NASDAQ:SBUX) belongs to Retail-Wholesale sector closed its last session with a loss of -1.22 percent and closed its previous trading session at $55.22. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $1.95. The company has the Market capitalization of $80.37 Billion. The company’s stock has a Return on Assets (ROA) of 0 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of 29.4 percent. The company reached its 52-Week high of $61.64 on Apr 8, 2016 and 52-Week low of $50.84 on Nov 4, 2016.

The growth estimate for Starbucks Corporation (NASDAQ:SBUX) for the current quarter is 15.4 percent. The projected growth estimate for the next quarter is 12.2 percent. The company’s stock has grown by 20.7 percent in the past 5 years. For the next 5 years, the company is expected to grow by 15.53 percent.

This company was Initiated by Buckingham Research on 21-Nov-16 to Neutral.

The 28 analysts offering 12-month price forecasts for Starbucks have a median target of 65.00, with a high estimate of 71.00 and a low estimate of 55.00. The median estimate represents a +17.71% increase from the last price of 55.22.

Financial History:

Following Earnings result, share price were UP 18 times out of last 28 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  7  times and missed earnings  1 times.

The consensus recommendation for Starbucks Corporation (NASDAQ:SBUX) is 1.52. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.52. In comparison, the consensus recommendation 60 days ago was at 1.55, and 90 days ago was at 1.52 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Starbucks Corporation to have earnings per share of $0.45.

Revenue is expected to range from 5.33 Billion to 5.5 Billion with an average of 5.41 Billion.

Company Profile:

Starbucks Corporation purchases and roasts high-quality whole bean coffees and sells them along with fresh, rich-brewed, Italian style espresso beverages, a variety of pastries and confections, and coffee-related equipments primarily through its company-operated retail stores. In addition to sales through its company-operated retail stores, Starbucks sells whole bean coffees through a specialty sales group and supermarkets. Additionally, Starbucks produces and sells bottled Frappuccino coffee drink and a line of premium ice creams through its joint venture partnerships and offers a line of innovative premium teas produced by its wholly owned subsidiary, Tazo Tea Company. The company’s objective is to establish Starbucks as the most recognized and respected brand in the world.